A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Mar 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.